HongMei Xia

HongMei Xia

Auto-generated profile, based on publicly available information

HongMei Xia

Departments of Oncology, the People’s Hospital of Yichun Affiliated to Clinical Medicine School of Yichun University in Jiangxi Province, Yichun, Jiangxi 336000

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2019 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
YWYin WeiHua
Yin WeiHua
GZGuPing Zhong
GuPing Zhong
HFHuizheng Fan
Huizheng Fan
HXHongMei Xia
HongMei Xia
Fluorouracil (5-FU) and oxaliplatin (L-OHP) are the most commonly used chemotherapy drugs for colorectal cancer, though resistance is common. Compound Sophora injection is a traditional Chinese medicine that can protect the liver against oxidation, improve immunity, and enhance sensitivity to chemotherapy; it may have an effect of reversing resistance in 5-FU- and L-OHP-resistant gastric cancer cells (5-FU/SW480 and L-OHP/SW480, respectively). A concentration gradient experiment was performed to identify a nontoxic dose of compound Sophora injection. 5-FU/SW480 and L-OHP/SW480 cells were treated with the nontoxic dose of compound radix Sophorae injection for 48 h, and changes in drug resistance to 5-FU and L-OHP were detected. Alterations in apoptosis and the cell cycle were assessed, as were the mRNA and protein levels of permeability glycoprotein (P-gp), annexin A1 (ANXA1), and ATP-binding cassette superfamily G member 2 (ABCG2). Flow cytometry showed a reduction in the number of cells in the G1 phase and an increase of cells in the S phase (P<0.05). mRNA and protein expression of P-gp and ABCG2 was significantly higher in 5-FU/SW480 and L-OHP/SW480 cell lines, and ANXA1 expression decreased significantly (P<0.05). Compound Sophora injection can reverse the drug resistance of 5-FU/SW480 and L-OHP/SW480 cell lines to 5-FU and L-OHP, respectively, possibly through a mechanism involving reduced expression of P-gp and ABCG2 but enhanced expression of ANXA1, which is the basis for the identification of clinical drug resistance in colorectal cancer.

1 January 2021 in International Journal of Surgery Oncology
Verified
Journal Article
Open access
PDF file
HXHongmei Xia
Hongmei Xia
XLXiaoJin Luo
XiaoJin Luo
FZFeng - Zhang
Feng - Zhang
YWYin WeiHua
Yin WeiHua
: The lack of effective treatment for CRPC is the leading cause of death in prostate cancer patients. However, CRPC exhibits high immunoglobulin (Ig) expression. Ig, one of the most important immune molecules, is a unique product of B lymphocytes and plays an important role in immune defence. The expression of IgG in malignant tumour tissues is positively correlated with the degree of tumour malignancy, and IgG promotes the proliferation and metastasis of tumour cells. A retrospective analysis of immunohistochemical pathological tissue sections collected from 50 patients with prostate cancer (PC) and 40 patients with prostatic hyperplasia from Yichun City People’s Hospital between May 2010 and May 2014 was conducted. The experimental group had an average age of 70.8 ± 2.7 years (58˜86 years old) and included 12 patients with low Ig expression and 38 with high Ig expression. The survival time of the former group was significantly longer than that of the latter group. In vitro, the expression of IgG protein and mRNA in PC3 cells was detected by Western blotting and RT-PCR. IgG expression was knocked down via small interfering RNA (siRNA), and the migration and invasion abilities of PC3 cells were assessed using a Transwell assay. Positive expression of tumour-derived IgG in prostate cancer can indicate poor prognosis of patients with prostate cancer, and high IgG expression promotes the invasion and metastasis of prostate cancer. Thus, IgG may become a therapeutic target in prostate cancer.